LONDON | Tue Jul 6, 2010 12:05am BST

LONDON (Reuters) - Britain's health cost watchdog has rejected Roche's cancer drug Herceptin for patients with stomach cancer, which means they will not get the drug paid for by the country's taxpayer-funded National Health Service (NHS).

The National Institute for Health and Clinical Excellence (NICE) said Tuesday it was rejecting the drug, whose generic name is trastuzumab, for gastric cancer "due to the uncertainty surrounding...

admin

Research and Markets: Threats to Avastin - Targeting the Vascular Endothelial Growth Factor Pathway

May 12, 2010 08:00 AM Eastern Daylight Time

DUBLIN--(BUSINESS WIRE)--Research and Markets (Threats to Avastin - Targeting the VEGF Pathway - Market Research Reports - Research and Markets) has announced the addition of the "Threats to Avastin - Targeting the VEGF Pathway" report to their offering.

Avastin is set to become the most successful cancer...

admin

5/11/2010 2:43 AM ET

(RTTNews) - Why it is profiled?
Watch out for potential upcoming catalysts

Biotechnology company ImmunoGen Inc.(IMGN: News ) develops targeted anticancer therapeutics using its Targeted Antibody Payload technology. In addition to developing its own product candidates, the company also selectively outlicenses its technology to other companies for use with their engineered antibodies.

The TAP (Targeted Antibody Payload) technology...

admin

Drug Now Used to Treat Erectile Dysfuncton May Enhance Delivery of Herceptin to Certain Brain Tumors


ScienceDaily (May 7, 2010) — New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors. The research, published in the journal PLoS ONE, could help doctors improve treatments...

admin

Tue Mar 30, 2010 8:06am EDT

March 30 (Reuters) - Patients are finally starting to reap some of the benefits of personalized medicine as drug and diagnostic companies begin to use newly-acquired genetic information to develop so-called companion diagnostics -- tests used to tailor drugs to a patient's specific genetic makeup.

A report by PricewaterhouseCoopers projects sales of diagnostic tests that analyze molecules like DNA or the chemical messenger RNA to double to $5...

admin